In addition, multiple studies have reported an increased risk of infection following the use of IL-17 inhibitors because IL-17 and IL-22 play an important role in enhancing innate barrier defense on the mucosal surface, with disruption of IL-17 production or signaling increasing the risk for fungal and bacterial infections [28, 39]. Here, IL17A is linked to bacterial infectious disease.